Sutro Biopharma Reports Strong Financials and Advances Clinical Milestones
Sutro Biopharma (STRO) has reported strong financial results for 2025, with $141.4 million in cash and a recent $110 million capital raise, extending its cash runway to Q2 2028. The company is advancing multiple clinical programs, including its ADC platform and collaborations with Astellas Pharma.
Topics: biotechnology clinical trials drug development financial results partnerships